Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update

Am Heart J. 2021 Mar:233:86-91. doi: 10.1016/j.ahj.2020.12.007. Epub 2020 Dec 29.

Abstract

In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.

Publication types

  • Meta-Analysis

MeSH terms

  • Benzhydryl Compounds / pharmacology
  • Cardiovascular System / drug effects*
  • Cause of Death
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Glomerular Filtration Rate / drug effects
  • Glucosides / pharmacology
  • Glycosides / pharmacology*
  • Hospitalization
  • Humans
  • Kidney / drug effects*
  • Kidney Diseases / drug therapy
  • Randomized Controlled Trials as Topic
  • Sodium-Glucose Transporter 1 / antagonists & inhibitors*
  • Sodium-Glucose Transporter 2 Inhibitors / pharmacology*

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Glycosides
  • SLC5A1 protein, human
  • Sodium-Glucose Transporter 1
  • Sodium-Glucose Transporter 2 Inhibitors
  • (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
  • empagliflozin